On March 5, Dechert is proud to host 2025 Life Sciences Day, an interdisciplinary program designed for in-house counsel, chief officers, and strategic investors. This dynamic half-day event offers a fantastic opportunity to network with industry leaders and delve into the latest trends and insights shaping the life sciences sector.
The event will
Happy Valentine’s Day. Today’s decision is about a rather un-romantic topic—holding companies. But that got us thinking about a lesser-known band out of San Francisco called Big Brother and the Holding Company. One of America’s most iconic vocalists got her start with the band. Big Brother and the Holding Company’s second album, Cheap Thrills, reached
The federal government and the Fourth Circuit have ruled that a charitable patient assistant program conceived to increase access to cancer drugs for needy patients violated the federal Anti-Kickback Statute. In an opinion long on canons of statutory interpretation and short on compassion for sick and dying patients, the Fourth Circuit upheld an HHS advisory
Yes, we are the Drug and Device Law Blog. Yes, we at times stray into other areas when we think a decision has application to our DDL world. Yes, today’s case is about a “drug” product. No, today’s case is not about a drug for humans. In fact, it really isn’t about a drug at
For any of our loyal readers looking to start the New Year with a healthy helping of CLE credit, a friendly reminder that four of your bloggers – Bexis, Steven Boranian, Stephen McConnell, and Lisa Baird – recently presented a free 90-minute CLE webinar on “The Good, the Bad and the Ugly: The best and
For any of our loyal readers looking to start the New Year with a healthy helping of CLE credit, a friendly reminder that four of your bloggers – Bexis, Steven Boranian, Stephen McConnell, and Lisa Baird – will be presenting a free 90-minute CLE webinar on “The Good, the Bad and the Ugly: The best
As 2024 has come to an end, our loyal readers have joined us in reviewing our ten worst decisions of the past year and our ten (plus runners up) best decisions of the past year.
As we do each year, we’re pleased to announce that four of your bloggers – Bexis, Steven Boranian, Stephen McConnell
We’re in New York this week for a legal conference that is always a good time. But, truth be told (and we are officers of the court, after all), several years ago we attended a conference sponsored by plaintiff lawyers and it was in every way a delightful affair. The judges did more than show
We are all familiar with the phrase—the rules are the rules. Meaning, rules should be enforced consistently, regardless of personal circumstances. Essentially the opposite of—rules are made to be broken. Meaning, exceptions to the rules abound. The law is full of both the former (strict adherence rules) and the latter (loose
We consistently defend the ability of physicians to engage in off-label use. Bexis helped lay the scholarly foundation for courts to utilize the term “off label use,” and two of his law review articles remain go-to reads on the subject. Not surprisingly, we follow medical malpractice decisions that address off label use. Back in 2009, Mark Herrmann (the Blog’s co-founder with Bexis), published a law review article articulating the reasons why package inserts should not be admitted as standard of care evidence in medical malpractice actions. More recently, we wrote a comprehensive post collecting case law rejecting the admission of package insert evidence to establish a violation of the standard of care by physicians who used drugs or devices off label. Today’s case is a detailed opinion from the Iowa Supreme Court joining what is now the majority view—that package inserts should not be admitted as substantive evidence of the standard of care.Continue Reading Package Inserts Are Not Admissible to Establish Standard of Care